CheckMate 9LA showed a 26% overall survival benefit for metastatic NSCLC patients treated with nivolumab and ipilimumab plus ...

A key opinion leader examines the overall survival data from the CheckMate 9LA study, which evaluated nivolumab plus ipilimumab plus chemotherapy in metastatic non-small cell lung cancer patients, and ...

PRINCETON, N.J.--(BUSINESS WIRE)-- Bristol Myers Squibb (NYSE: BMY) today announced the first presentation of results from the Phase 3 CheckMate -9LA trial, which demonstrated a statistically ...

Study evaluated Opdivo plus low-dose Yervoy given concomitantly with two cycles of chemotherapy vs. chemotherapy alone for the first-line treatment of advanced non-small cell lung cancer PRINCETON, ...

The KRYSTAL-12 study remains ongoing to assess the additional key secondary endpoint of overall survival. On Monday, Bristol Myers announced results from three updated analyses from the CheckMate -77T ...

Please provide your email address to receive an email when new articles are posted on . The addition of nivolumab and low-dose ipilimumab to first-line chemotherapy significantly extended OS for ...

Overall survival with circulating tumor DNA-guided therapy in advanced non-small cell lung cancer. This is an ASCO Meeting Abstract from the 2021 ASCO Annual Meeting I. This abstract does not include ...

Combination nivolumab (Opdivo) and ipilimumab (Yervoy) with chemotherapy offered a durable survival benefit versus chemotherapy alone in advanced non-small cell lung cancer (NSCLC) with brain ...

Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window A first-line ...

The Food and Drug Administration (FDA) has approved the combination of Opdivo (nivolumab; Bristol Myers Squibb) plus Yervoy (ipilimumab; Bristol Myers Squibb) and 2 cycles of platinum-doublet ...

Bristol-Myers Squibb Company announced that CheckMate -9LA, a pivotal phase 3 trial evaluating Opdivo (nivolumab) plus low-dose Yervoy (ipilimumab) given concomitantly with two cycles of chemotherapy ...